Evidence map›Paper›PMID 41606691›Full record

ReviewBiomarker research2026

Isolation and typing techniques for circulating tumor cells.

Shuyan Wu, Shunzi Rong, Anqi He, Yong Xia, Fuyan Xu

Abstract readReview
In one paragraph

Review in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shuyan Wu *Joint Lab of Reproductive Medicine of SCU-CUHK, Lab of Reproductive Genetics and Epigenetics, Department of Obstetrics/Gynecology, Key Laboratory of Birth Defects and Related Disease of Women and Children of MOE, West China Second University Hospital, West China School of Medicine, Sichuan University, Chengdu, 610041, China.
Shunzi Rong *Joint Lab of Reproductive Medicine of SCU-CUHK, Lab of Reproductive Genetics and Epigenetics, Department of Obstetrics/Gynecology, Key Laboratory of Birth Defects and Related Disease of Women and Children of MOE, West China Second University Hospital, West China School of Medicine, Sichuan University, Chengdu, 610041, China.
Anqi He *Joint Lab of Reproductive Medicine of SCU-CUHK, Lab of Reproductive Genetics and Epigenetics, Department of Obstetrics/Gynecology, Key Laboratory of Birth Defects and Related Disease of Women and Children of MOE, West China Second University Hospital, West China School of Medicine, Sichuan University, Chengdu, 610041, China.
Yong XiaRehabilitation Medicine Center, Rehabilitation Medicine Research Institute, Key Laboratory of Rehabilitation Medicine in Sichuan Province, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, 610041, China. yxia4@scu.edu.cn.
Fuyan XuJoint Lab of Reproductive Medicine of SCU-CUHK, Lab of Reproductive Genetics and Epigenetics, Department of Obstetrics/Gynecology, Key Laboratory of Birth Defects and Related Disease of Women and Children of MOE, West China Second University Hospital, West China School of Medicine, Sichuan University, Chengdu, 610041, China. 962766607@qq.com.

Funding

National Natural Science Foundation of China 82573560Sichuan Science and Technology Program 2025ZNSFSC0559
6 · The paper itself

Abstract

Circulating tumor cells (CTCs) are tumor cells that detach from primary tumors or metastatic sites and enter the peripheral blood. As an important biomarker for liquid biopsy, their detection and analysis have offered a promising avenue in early diagnosis, treatment response monitoring, and prognosis evaluation of tumors. Given the extreme rarity and high heterogeneity of CTCs, efficient and accurate separation and typing have become a primary research focus. This article systematically reviews the mainstream technologies for CTC separation and enrichment, including positive/negative selection based on immune markers, size/deformation/charge separation based on physical properties, and emerging microfluidic platforms; Furthermore, we discuss subtyping strategies for CTC phenotypes and genotypes, encompassing the combined application of surface markers such as EpCAM, CK, Vimentin, gene mutation and copy number variation analysis, transcriptome and proteomic feature analysis, etc.; Additionally, we highlight advancements in functional evaluation techniques such as single-cell culture, metabolic labeling, and in vivo tracking which provide insights into the stemness, drug resistance, and metastatic propensity of CTCs. Finally, we explore the prospects of integrating artificial intelligence and multi omics in CTC typing, pointing out that despite rapid technological progress, challenges in standardization, detection sensitivity, and clinical validation remain significant hurdles to their routine translational application. The review aims to provide a technical framework and cutting-edge perspective for CTC research, and promote its application in personalized tumor management.

Indexed as

Cancer biomarkersCell isolation technologiesCirculating tumor cellsLiquid biopsyPhenotypic and molecular typing

Identifiers

PMID41606691
PMCPMC12857121

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.